IRINOTECAN INTAS irinotecan hydrochloride trihydrate 40 mg/2 mL concentrated injection vial

País: Australia

Idioma: inglés

Fuente: Department of Health (Therapeutic Goods Administration)

Ingredientes activos:

irinotecan hydrochloride trihydrate, Quantity: 40 mg

Disponible desde:

Accord Healthcare Pty Ltd

Designación común internacional (DCI):

irinotecan hydrochloride trihydrate

formulario farmacéutico:

Injection, concentrated

Composición:

Excipient Ingredients: water for injections; sodium hydroxide; hydrochloric acid; sorbitol; lactic acid

Vía de administración:

Intravenous Infusion

Unidades en paquete:

1 vial

tipo de receta:

(S4) Prescription Only Medicine

indicaciones terapéuticas:

Irinotecan hydrochloride is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. Irinotecan hydrochloride is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Resumen del producto:

Visual Identification: A pale yellow clear solution; Container Type: Vial; Container Material: Glass Type I Coloured; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Estado de Autorización:

Licence status A

Fecha de autorización:

2014-06-12